3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Withdrawn
1
Recruiting
1
Completed
1
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other solid neoplasm
1
Conditions
Melanoma
14
Uterine Cervical Neoplasms
2
Prostatic Neoplasms
2
Neoplasm Metastasis
2
Hematologic Neoplasms
2
Colorectal Neoplasms
2
Carcinoma, Non-Small-Cell Lung
2
Xeroderma Pigmentosum
1
Vulvar Neoplasms
1
Vaginal Neoplasms
1
Uveal Melanoma
1
Turcot syndrome
1
Triple Negative Breast Neoplasms
1
Solid Tumor
1
Sarcoma
1
Neuroblastoma
1
Multiple Myeloma
1
Lymphoma
1
Lymphatic Metastasis
1
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Hemangiosarcoma
1
Esophageal Neoplasms
1
Colorectal Neoplasms, Hereditary Nonpolyposis
1
Colorectal Cancer Metastatic
1
Colonic Neoplasms
1
Central Nervous System Neoplasms
1
Carcinoma, Renal Cell
1
Carcinoma, Merkel Cell
1
Carcinoma
1
Interventions
vistusertib
2
toripalimab
1
tislelizumab
1
tanespimycin
1
sargramostim
1
roniciclib
1
abemaciclib
1
Letrozole
1
Ipilimumab
1
Hydroxychloroquine
1
Fulvestrant
1
Anastrozole
1
Albumin-Bound Paclitaxel
1
AMG 337
1
4-toluenesulfonamide
1
130-nm albumin-bound paclitaxel
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Withdrawn
×
Solid Tumor
×
Ipilimumab
×
Clear all
NCT05284214
2023-09-15
SALIENT
Partner Therapeutics, Inc.
Phase 2
Withdrawn